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Abstract
Background: Mutations in methylmalonyl-CoA mutase cause methylmalonic acidemia, a common organic aciduria.
Current treatment regimens rely on dietary management and, in severely affected patients, liver or combined liver-kidney
transplantation. For undetermined reasons, transplantation does not correct the biochemical phenotype.
Methods: To study the metabolic disturbances seen in this disorder, we have created a murine model with a null allele
at the methylmalonyl-CoA mutase locus and correlated the results observed in the knock-out mice to patient data. To
gain insight into the origin and magnitude of methylmalonic acid (MMA) production in humans with methylmalonyl-CoA
mutase deficiency, we evaluated two methylmalonic acidemia patients who had received different variants of combined
liver-kidney transplants, one with a complete liver replacement-kidney transplant and the other with an auxiliary liver
graft-kidney transplant, and compared their metabolite production to four untransplanted patients with intact renal
function.
Results: Enzymatic, Western and Northern analyses demonstrated that the targeted allele was null and correctable by
lentiviral complementation. Metabolite studies defined the magnitude and tempo of plasma MMA concentrations in the
mice. Before a fatal metabolic crisis developed in the first 24–48 hours, the methylmalonic acid content per gram wet-
weight was massively elevated in the skeletal muscle as well as the kidneys, liver and brain. Near the end of life, extreme
elevations in tissue MMA were present primarily in the liver. The transplant patients studied when well and on dietary
therapy, displayed massive elevations of MMA in the plasma and urine, comparable to the levels seen in the
untransplanted patients with similar enzymatic phenotypes and dietary regimens.
Conclusion: The combined observations from the murine metabolite studies and patient investigations indicate that
during homeostasis, a large portion of circulating MMA has an extra-heptorenal origin and likely derives from the skeletal
muscle. Our studies suggest that modulating skeletal muscle metabolism may represent a strategy to increase metabolic
capacity in methylmalonic acidemia as well as other organic acidurias. This mouse model will be useful for further
investigations exploring disease mechanisms and therapeutic interventions in methylmalonic acidemia, a devastating
disorder of intermediary metabolism.
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Background
Methylmalonic acidemia is the biochemical hallmark of a
group of autosomal recessive genetic metabolic disorders
that prevent the body from converting L-methylmalonyl-
CoA into succinyl-CoA[1]. These disorders are caused by
mutations in the methylmalonyl-CoA mutase apoenzyme
or by impaired synthesis of the enzymatic cofactor,
5'deoxyadenosylcobalamin [2,3]. Affected individuals
display massive elevations of methylmalonic acid (MMA)
in body tissues and fluids, have a well-recognized meta-
bolic phenotype characterized by extreme metabolic fra-
gility, and a poor outcome marked by early mortality and
substantial lifelong morbidity [4-8].
Mutations in the methylmalonyl-CoA mutase (MUT)
gene are the cause of mut class methylmalonic acidemia.
Two enzymatic phenotypes within this class are recog-
nized. In muto, there is no detectable or residual enzyme
activity. In mut-, enzyme activity is markedly reduced but
can sometimes be stimulated in vitro with supraphysiolog-
ical concentrations of vitamin B12 [4,9-11]. The correla-
tion between in vitro and  in vivo vitamin B12
responsiveness in patients classified as mut- is uncertain,
since most do not demonstrate a physiological response
to parenteral cobalamin [12-14]. Typically, patients with
muto methylmalonic acidemia display more severe bio-
chemical and clinical phenotypes than patients who har-
bor cofactor responsive lesions [4]. In a recent clinical
study, vitamin B12 unresponsive patients had a median
survival of six years [7].
The treatment of isolated methylmalonic acidemia was
established in the 1960s and consists of alkali replace-
ment and nutritional management, mainly designed to
limit amino acid precursors [15-17]. Carnitine supple-
mentation and intermittent antibiotic therapy are newer
measures, whose efficacy has not been determined [18-
21]. The precise etiology of the complications of methyl-
malonic acidemia is uncertain, and even well-treated
patients remain at risk for intermittent decompensation,
pancreatitis, metabolic infarction of the basal ganglia, and
renal failure[6-8,22-24].
Solid organ transplantation has been used as a therapy for
methylmalonic acidemia and a few patients have received
liver, kidney, and combined liver-kidney transplants [25-
34]. Liver and liver-kidney transplant recipients do not
experience ketoacidotic attacks, but remain at risk for
renal disease[29] and metabolic infarction of the basal
ganglia [30]. They also exhibit persistent methylmalonic
acidemia/aciduria [33] and may have extreme elevations
of MMA in the cerebrospinal fluid (CSF) [34]. The origin
of MMA production and the magnitude of MMA eleva-
tions in transplant patients have not been carefully stud-
ied.
We created a mouse model of muto  methylmalonic
acidemia to investigate the pathophysiological mecha-
nisms of the disease and study the etiology of MMA pro-
duction in the disorder. In this report, we describe the
metabolic phenotype of the muto animals and compare it
to the human condition in the post-transplant state. Our
data suggest that the extra-hepatorenal metabolism of
propionyl-CoA provides the major pool of metabolites
seen in methylmalonic acidemia and highlights the role
that skeletal muscle plays in the pathophysiology of this
common organic aciduria.
Methods
Construction of the exon 2 floxed, exon 3 deleted 
methylmalonyl-CoA mutase allele
A 129 Sv/Ev BAC clone containing the murine methylmal-
onyl-CoA mutase gene was used to prepare a targeting
construct. In brief, a set of contiguous EcoRI restriction
fragments containing the 5'end of the gene and first
through fourth exons was assembled in pBluescript. The
first contained a fragment that harbored the second and
third exons of the gene. A loxP linker was introduced into
the 5' EcoRI site. The linker carries a unique ApaLI site.
The two 5' genomic EcoRI fragments were added sequen-
tially, followed by the addition of a PstI fragment contain-
ing a portion of exon 3 to the 3' end. A cassette derived
from pHR1 that carried a loxP site, the pMC1 promoter,
the neomycin resistance gene, and the Sv40 poly-A signal
was placed in between the unique AvrII site and the
Bsu36I site in the targeting construct[35]. A diphtheria
toxin-A fragment cassette under the control of the pMC1
promoter was next inserted at the 5' end of the construct
in the reverse orientation to generate the targeting con-
struct[36]. ES clones were screened using combination of
long-range PCR/enzyme digestion and Southern blotting.
Primers that flank the 5' loxP site were used to genotype
the animals. (See additional file 1 and additional file 2 for
the representative results, PCR conditions, and primer
sequences). The National Human Genome Research Insti-
tute Animal Care and Use Committee approved the ani-
mal experiments.
Biochemical Characterization and Lentiviral 
Complementation
Mut mutant animals were identified by genotyping and
metabolic analysis using the para-nitroanaline reaction
(See additional file 1 for representative results of meta-
bolic screening) [37]. Organs were harvested and nucleic
acids extracted using the DNeasy Tissue kit and RNeasy
Total RNA Isolation from Lipid Tissues kit (Qiagen). The
Northern blot was performed with the Northern Max-Gly
kit (Ambion) following the manufacturer's protocol. 20
µg of total RNA, derived from the liver of Mut null or wild-
type neonatal mice, was used for Northern blotting. The
probe for the mouse gene was a portion of the cDNA,BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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located between the start codon at the 5' end and an NcoI
site at position 1187, encoding exons 1–5. The blot was
stripped and probed with an actin cDNA, which was pro-
vided by Ambion as a loading control.
Whole cell extracts from the liver and murine embryonic
fibroblast cell lines were analyzed by immunoblotting
and were probed with rabbit polyclonal antisera raised
against the murine methylmalonyl-CoA mutase enzyme
[38] or beta-actin (Abcam, Cambridge, MA). The anti-
mutase antibody was used at a dilution of 1:750, and
beta-actin was used at 1:5,000. Goat anti-rabbit (Chemi-
con, Temecula, CA) was used as a secondary antibody at a
dilution of 1:10,000. Chemiluminescent detection was
performed with reagents from Pierce. Recombinant
murine methylmalonyl-CoA mutase enzyme [39] was
used to verify the specificity of the rabbit anti-mutase
antisera and to provide a positive control in Western blot
analysis experiments.
Methylmalonyl-CoA mutase activity was determined indi-
rectly by measuring [1-14C] propionate incorporation into
macromolecules as described[40]. All propionate incor-
poration assays were performed in triplicate. [1-14C]
Sodium propionate was purchased (Perkin Elmer, Cam-
bridge, MA) as a custom preparation at a specific activity
of 55.0 mCi/mmol (2 mCi/ml).
Murine embryonic fibroblast cell lines were prepared after
harvesting embryos on day E12.5. The cell lines were gen-
otyped and expanded prior to use. A recombinant lentivi-
rus that expressed the murine methylmalonyl-CoA
mutase was prepared by cloning a sequence-verified, full-
length murine methylmalonyl-CoA mutase cDNA into
pLenti6 (Invitrogen, Carlsbad, CA). The lentiviral con-
struct has the Mut gene driven by the CMV promoter and
the backbone carries a blasticidin cassette driven by the E7
promoter. A control lentivirus expressing EGFP cloned in
an identical fashion was also prepared and used in paral-
lel for correction experiments.
All viral stocks were prepared according to manufacturers
instructions. Mut null MEF cell lines were infected with
lentiviral stocks expressing either murine methylmalonyl-
CoA mutase or eGFP. The transduced MEFs were selected
and expanded on DMEM with 5 percent fetal bovine
serum containing 2.5 µg/ml blasticidin prior to [1-14C]
propionate incorporation studies.
Metabolic Studies
Plasma was isolated from animals immediately after euth-
anization by collecting blood in tubes that contained 1–5
µl of diluted sodium heparin. The samples were immedi-
ately centrifuged, the plasma removed, diluted in water,
and stored at -80°C in a screw top tube for later analysis.
The mice underwent gentle bladder massage to produce
1–10 µl of urine that was immediately analyzed or diluted
and stored in a similar fashion as the plasma. Organ dis-
sections were performed under a dissecting microscope to
remove the brain, liver, skeletal muscle, and kidneys.
Organs were weighed and snap frozen prior to storage at -
80°C and subsequent processing.
Two methods were used to measure MMA in the mice.
Plasma, urine, and organ extracts were analyzed by gas
chromatography-mass spectrometry with stable isotopic
internal calibration to measure MMA and 2-methylcitrate
isomers I and II[41]. The para-nitroanaline reaction was
used for rapid identification of affected animals[37].
Patient Studies
Patient studies were conducted in compliance with the
Helsinki Declaration and were approved by the National
Human Genome Research Institute Institutional Review
Board as part of NIH study 04-HG-0127 "Clinical and
Basic Investigations of Methylmalonic Acidemia and
Related Disorders" after informed consent was obtained.
Metabolic parameters and creatinine clearance were meas-
ured during two consecutive 24-hour urine collections
and were used to estimate the glomerular filtration rate
(GFR) and MMA output.
Two patients had undergone combined liver-kidney trans-
plantation as a treatment for muto class methylmalonic
acidemia prior to enrollment. Briefly, the patient labeled
L(A)KT, a 19-year old Caucasian female, was diagnosed
on the second day of life following an episode of hypo-
thermia and lethargy. At age 12, she received a cadaveric
renal transplant and subhepatic heterotopic auxiliary liver
transplant[28]. At the time of these studies, she was receiv-
ing 0.8 g/kg/d whole protein. Patient LKT, a 27-year old
Mexican-American female, was diagnosed in the neonatal
period. At age 22, she received an orthotopic liver trans-
plant followed by a kidney transplant two years later[29].
At the time of these studies, she was receiving 0.5 g/kg/d
whole protein. The other patients (N = 4) ranged in age
from 4 to 21 years and have not received transplants. All
patients harbored complementation status-defined muto
class lesions and were selected as a comparator group
because they had identical enzymatic phenotypes and
importantly, preserved renal function, with measured cre-
atinine clearances greater than 40 percent of predicted. All
patients were well at the time of hospitalization and were
individually prescribed high energy, low protein diets that
provided between 0.3–0.9 g/kg/d whole protein. One
patient (Pt 4) also received supplemental isoleucine.
Statistics
Statistical manipulations were carried out using Statistical
Analysis Software (SAS) version 9 (SAS Institute, Cary,BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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North Carolina, USA). Differences in the plasma and uri-
nary MMA concentrations between mutant mice over
time and patient groups was determined by one-way
ANOVA and adjusted for multiple comparisons using the
Tukey-Kramer method. Tissue metabolites were analyzed
using a mixed model ANOVA to account for both random
and fixed effects. The model included the effects of time,
organ, and organ by time interaction. p-values for the
higher-level interaction comparisons were adjusted using
bootstrap simulation[42]. p-values of 0.05 or less were
considered statistically significant.
Results
Methylmalonyl-CoA Mutase Mutant Mice
Homologous recombination in mouse embryonic stem
cells was used to engineer a deletion in the third exon of
the methylmalonyl-CoA mutase (Mut) gene and to flank
the exon 2 with loxP sites to create a versatile null allele,
suitable for Cre-mediated genomic manipulations [43]
(Figure 1). RNA and enzymatic assays verified that the Mut
mutant allele abolished the function of the methylmalo-
nyl-CoA mutase enzyme (Figure 2). Total RNA was iso-
lated from the livers of Mut deficient mice and wild-type
controls. Northern blot experiments using a portion of the
murine cDNA encompassing the first through fifth exons
as a probe showed no hybridization signal in Mut null
liver RNA (Figure 2A). The wild type sample had a large
and strongly reactive band of approximately 3.0 kb. RT-
PCR experiments yielded no product in Mut  null liver
RNA when amplified with primers that flanked the dele-
tion (Exons 2–6) or were anchored within the deletion
(Exons 3–4) (data not shown, see additional file 2 for
primer sequences and RT-PCR conditions). Actin hybridi-
zation (Figure 2A) and amplification of GAPDH by RT-
PCR on both samples confirmed that the RNA was intact
(data not shown). Western blotting using an anti-mutase
antibody revealed complete loss of protein in the liver
extracts (Figure 2B).
Murine embryonic fibroblasts (MEF) derived from wild-
type and Mut mutant embryos were isolated and used to
construct cell lines. The cells were genotyped and used to
assess the functional activity of methylmalonyl-CoA
mutase by [1-14C]propionate incorporation and respon-
siveness to vitamin B12. Compared to wild-type cells, the
Mut knock-out cell lines were devoid of methylmalonyl-
CoA mutase protein (see additional file 3), incorporated
very low levels of [1-14C] propionate into macromole-
cules, and exhibited no stimulation by exogenous vitamin
B12 (Figure 2C).
The cell lines were then studied in complementation
experiments. The full length Mut cDNA was placed behind
the CMV promoter in a lentivirus that carried an inde-
pendently expressed blasticidin-resistance cassette and
was used to produce viral stocks. Integrated proviruses
expressed both genes, and blasticidin selection was used
to enrich for transduced cells. [1-14C] propionate incorpo-
ration showed an increase in mutase activity to near wild-
type levels in the transduced Mut null MEF cell lines (Fig-
ure 2C) whereas a control GFP did not.
Metabolic Studies in the Mut mutant Mice
In the neonatal period, the Mut null animals appeared
well until 12 to 24 hours of life, when the size of the milk
spot in the stomach decreased and dehydration occurred.
The mice typically perished 24 to 36 hours after birth with
respiratory distress and non-necrotic lipidotic changes in
the liver. Two of the eight Mut null mice that were exam-
ined had pulmonary hemorrhages, but most had nonspe-
cific post-mortem findings. Increased intracranial
pressure was suggested in some animals because the brain
appeared compressed against the dura mater on histolog-
ical examination. Organic acids and amino acids from the
plasma and urine were analyzed throughout the life of the
mutant and control littermates.
On several occasions, embryos were harvested on day 16
of gestation to examine the distribution of genotypes and
look for possible prenatal manifestations of methyl-
malonic acidemia, such as growth retardation and malfor-
mation. In the four litters examined, mice were present in
approximately 1:2:1 ratios, and homozygous Mut mutant
animals were indistinguishable from heterozygous and
homozygous wild-type (WT) animals. Plasma methyl-
malonic acid concentrations in the heterozygous and
homozygous WT animals, measured on embryonic day
Targeting construct and null allele Figure 1
Targeting construct and null allele. (A) An overview of the 
targeting construct and disrupted allele. Selected restriction 
sites are indicated. The initiator codon lies in the second 
coding exon and the coenzyme A binding pocket in the third 
coding exon. Recombination sites (loxP), the diptheria toxin 
A cassette (DTA) and neomycin resistance gene (NEO) are 
shown. The location of genotyping primers that flank the 5' 
loxP site are indicated by A and B.BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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19, were equal at the lower limit of assay detection in
diluted samples. In contrast, the Mut  mutant animals
demonstrated significant elevations of plasma MMA, with
an average concentration of 176 µM (Figure 3A). Amni-
otic fluid also showed increased methylmalonic acid in
the Mut mutant (average = 117 µM) compared to wild-
type animals (average = 5.3 µM) (Figure 3B).
Mut  mutant and control animals were harvested at
approximately 4 to 6 hours of life for metabolite studies.
All the animals had similar weights, developed milk spots,
and appeared vigorous. Heterozygous and WT animals
had identical biochemical parameters with diluted
plasma MMA concentrations near the lower limits of assay
detection, but the Mut null mice displayed plasma MMA
levels in the 700 µM range (Figure 3A) with massive meth-
ylmalonic aciduria (Figure 3B).
At 8 to 12 hours of life, while still well and feeding, the
neonatal  Mut  animals displayed increasing methyl-
malonic acidemia and methylmalonic aciduria (Figure 3),
with plasma MMA concentrations in the 1.2 mM range
and urine MMA levels greater than 20 mM. Control litter-
mates had plasma MMA levels similar to those measured
at earlier times.
At the end of life, the Mut null mice had plasma MMA
concentrations of 2.2 mM, which were not drastically
higher than those of the neonatal animals at 8 to 12 hours
of life (Figure 3A). As the mice developed agonal respira-
tions, the plasma MMA concentrations rose to greater
than 2 mM. Although the animals appeared in extremis, a
frank acid/base imbalance caused by MMA seems
unlikely, given the plasma MMA concentration at this
time.
The pattern of increases in the concentration in the
plasma was highly significant within the mutant groups
over time: prenatal vs. 4–6 hours [F (1,6) = 107; p <
0.0001], 4–6 hr vs 8–12 hours [F (1,6) = 54; p < 0.0001]
and 8–12 hours vs 20–24 hours [F (1,4) = 152; p <
0.0001]. The urinary metabolites showed a similar pattern
with prenatal vs. 4–6 hours [F (1,6) = 30; p = 0.0002] and
4–6 hr vs 8–12 hours [F (1,6) = 49; p < 0.0001]. However,
at 8–12 hours vs 20–24 hours the differences were not sig-
nificant [F (1,4) = 0.14; p = 0.7143].
Organs were examined for MMA content throughout the
life of the animals. In the prenatal Mut mutant mice, a 19-
fold increase in the MMA content of the kidney was
observed, with other organs increased only 3–4 fold over
wild-type animals (see additional file 4 for a graph of the
fold change). At 8 to 12 hours of age, skeletal muscle and
kidney MMA levels exceeded the MMA levels of the brain
and liver in mutants (Figure 4) but were not significantly
greater. At the end of life, however, the MMA content and
Northern, Western, enzymatic and correction studies Figure 2
Northern, Western, enzymatic and correction studies. (A) Northern analysis of total RNA extracted from wild-type and Mut 
knockout livers. The mutase message is apparent in the wild-type sample and absent in the Mut mutant liver. Actin hybridiza-
tion after stripping and reprobing shows the RNA to be intact and equally reactive. (B) Western blotting using anti-mutase 
antisera reveals a band of ~80 kd in the wild-type liver extracts that is completely absent from the mutant liver extracts. (C) [1-
14C] propionic acid incorporation, with and without vitamin B12, in various cell lines, expressed as percent of wild-type activity. 
The wild type activity varied between days and ranged from 5.0–15.0 nmol C14 propionate/mg protein/18 hrs. Error bars sur-
round the standard deviation from triplicate measurements. The corrected Mut null murine cell line (labeled MUTO + MCM 
LENTI) shows restored propionate flux when compared with the Mut null and GFP-transduced cell lines.BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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fold change was increased in the mutant liver, as was the
MMA content of the skeletal muscles, kidneys, and brain
in descending order (see additional file 4 for a graph of
the fold change). Within the affected animal groups,
organ specific differences over time were examined for sig-
nificance using a mixed model ANOVA. First, an effect of
time was assessed to examine the hypothesis that MMA
concentrations varied over time in an organ specific fash-
ion [F (6,12) = 6.7, p = 0.002]. The effect of time on MMA
concentration in each organ type was next determined,
with liver [F (2,16) = 43.7, p < 0.0001), skeletal muscle
[F(2,16) = 11.8, p = 0.0007) and kidney [F (2,16) = 7.9, p
= 0.004) displaying a statistical significant pattern of
increasing as time progressed. The changes in brain
metabolites [F (2,16) = 2.8, p = 0.09] showed a trend
toward increasing over time but did not achieve signifi-
cance. Next, pair wise contrasts were constructed from the
mixed model results in order to compare all tissue types
and all sample times. The corresponding p values,
adjusted for multiple comparison after bootstrap simula-
tion, were examined for significance using paired t-tests.
The most important trend was that the MMA content of
the liver at 24 hours was significantly greater than skeletal
muscle (p = 0.002 at 8 hours, p = 0.05 at 24 hours), brain
(p = 0.002 at 8 hours, p = 0.0016 at 24 hours), or kidney
(p = 0.0023 at 8 hours, p = 0.0072 at 24 hours). Further-
more, despite the fact that the skeletal muscle had the
highest MMA content at 8 hours, there were no statisti-
cally significant differences between organs at 8 hours.
Comparison between the mutant versus wild type and
heterozygous animals for plasma and tissue metabolites
was striking at all points. Because many wild type and het-
erozygote animals had MMA levels at the lower limit of
Methylmalonic acid concentration by tissue type over time Figure 4
Methylmalonic acid concentration by tissue type over time. 
(A) MMA concentrations expressed as nmol per gram of tis-
sue. The values are averages from prenatal [embryonic day 
19] (N = 3), neonatal [8–12 hour] (N = 3), and metabolic cri-
sis [20–24 hour] (N = 2) mutant animals. Values for age-
matched control littermates (N = 2) for each time point are 
not depicted on this graph but were used to plot the fold 
change, depicted in additional file 4. The error bars surround 
the standard deviation for the prenatal time point and the 
range observed at the stage of metabolic crisis. p-values for 
the mutant versus age matched controls were <0.01 for all 
tissues. An asterisk * designates a significant p-value. In the 
mutants, the MMA content of the liver at 24 hours was signif-
icantly greater than skeletal muscle (p = 0.002 at 8 hours, p = 
0.05 at 24 hours), brain (p = 0.002 at 8 hours, p = 0.0016 at 
24 hours), or kidney (p = 0.0023 at 8 hours, p = 0.0072 at 24 
hours). However, only the difference between the liver sam-
ples at the 24-hour time point and other tissues at the 8 and 
24-hour time points were significant with a p-value less than 
0.05.
Pre- and postnatal plasma and urine methylmalonic acid lev- els Figure 3
Pre- and postnatal plasma and urine methylmalonic acid lev-
els. (A) MMA concentrations (µM) measured in the plasma 
over time. Error bars surround the standard deviation. Wild-
type (N = 4–8 age matched littermates at each time point, 
not displayed), Mut null prenatal [E19] (N = 3), Mut null post-
natal 4–6 hours (N = 4), Mut null postnatal 8–12 hours (N = 
4), and Mut null postnatal 20–24 hours (N = 4). Low-level 
wild-type values not displayed. An asterisk * designates a sig-
nificant p-value, calculated using a one-way ANOVA with 
Tukey-Kramer adjustment, for comparison between advanc-
ing time points. Prenatal (value = 176 µM) vs. 4–6 hours [F 
(1,6) = 107; p < 0.0001], 4–6 hr vs 8–12 hours [F (1,6) = 54; 
p < 0.0001] and 8–12 hours vs 20–24 hours [F (1,4) = 152; p 
< 0.0001]. At all time points, the mutants were different 
from the unaffected littermates with p-values less than 0.001. 
(B) MMA concentrations (mM) in urine or amniotic fluid on 
day E19 (value = 117 µM) from the samples above. An aster-
isk * designates a significant p-value, calculated using a one-
way ANOVA with Tukey-Kramer adjustment, for compari-
son between advancing time points. Prenatal vs. 4–6 hours [F 
(1,6) = 30; p = 0.0002] and 4–6 hr vs 8–12 hours [F (1,6) = 
49; p < 0.0001]. However, at 8–12 hours vs 20–24 hours the 
differences were not significant [F (1,4) = 0.14; p = 0.7143]. 
In all cases, the mutants were different from the unaffected 
littermates (not displayed) with p-values less than 0.001.BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
Page 7 of 11
(page number not for citation purposes)
assay detection, detailed comparisons between these
groups were not included in our analysis.
The contribution of other metabolites and cellular proc-
esses to the clinical phenotype was also examined. In par-
ticular, 2- methylcitrate (2-MC) was elevated in the
affected mice in all fluids and tissues examined (data not
shown). Both in humans with cobalamin deficiency syn-
dromes [41] and in the mutant mice, the ratio of the dias-
teromer 2-MCI to 2-MCII was greater in the brain than in
the periphery (see additional file 5 for the ratios of the
diasteromers in the different tissues over time) as the ill-
ness progressed.
Patient Studies
Whole body output of MMA was estimated from the
timed urine collections of six patients with muto methyl-
malonic acidemia, including two who had undergone
combined liver and kidney transplantation (Figure 5). The
two muto transplant patients, one with an auxiliary liver-
kidney transplant (Figure 5, labeled L(A)KT) and one with
a replacement liver-kidney transplant (Figure 5, labeled
LKT), had nearly identical plasma MMA concentrations,
in the 260 µM range (normal < 0.3 µM), when treated
with dietary therapy. Compared to other muto patients
with measured glomerular filtration rates greater than
40% predicted for age who were also treated with high cal-
orie, propiogenic precursor restricted diets, the plasma
levels of MMA in the transplanted patients approximated
that observed in non-transplanted patients, and the 24-
hour urinary MMA output [44] (measured in millimoles
of MMA in the urine/kg body weight/day) displayed a
comparable elevation. The average values for the plasma
MMA concentration and MMA output were calculated and
compared between the two groups. Neither the plasma
metabolites [F(1,4) = 0.40, p = 0.56] or the MMA output
[F (1,4) = 0.70, p = 0.44] was significantly different
between the groups. The glomerular filtration rate (GFR)
was measured with two consecutive 24-hour urine collec-
tions and found to be greater than 70 ml/min in the trans-
planted patients, with normal values of other renal
parameters, such as fractional excretion of sodium and
urinary amino acids. This indicates that renal dysfunction
is not a contributing factor to the methylmalonic
acidemia and aciduria observed in these transplanted
individuals. Minimal biochemical data was available on
the transplant patients when they had preserved renal
function and precluded a direct comparison to the effect
of combined organ transplantation in each patient.
Discussion
Our biochemical characterization of methylmalonic
acidemia in murine and human systems has provided us
with important new insights not examined in studies of a
different murine model of methylmalonic acidemia [45].
For example, during gestation (E19) the plasma MMA of
muto mice was in the 170 µM range, much greater than the
30 µM concentration seen in amniotic fluid (urine) sam-
ples from mothers known to carry muto fetuses[46]. These
high plasma MMA levels indicate aberrant prenatal
metabolism and suggest that the animals may be born
partly intoxicated due to the chronicity and magnitude of
their exposure to MMA and related metabolites. Prenatal
exposure to an abnormal metabolic milieu may explain
the onset of clinical symptoms in some of the neonates
with muto methylmalonic acidemia in the first 24 hours of
life and the later presentations seen in patients with less
severe blocks[4]. In utero metabolic changes and the
effects on growth and development have become an
increasingly recognized feature in disorders of the electron
transport chain [47] and future studies of in utero metab-
olism in the muto mice will examine whether the massive
metabolite elevations observed have physiological conse-
quences on energy metabolism.
The pattern of organ MMA concentrations observed as the
illness progresses in mice reveals several important trends
that can be directly correlated to patients. While the mice
are alive and feeding, their plasma MMA concentration is
1.2 mM and the skeletal muscle contains the highest aver-
age concentration of MMA per milligram of wet-weight
tissue. This suggests that the skeletal muscle is generating
significant amounts of MMA. The notion of extra-hepato-
renal production of MMA is supported by the studies on
the human combined liver-kidney transplant patients,
who have massive MMA output (Fig. 5B) and enormously
elevated plasma MMA levels comparable to those seen in
non-transplanted methylmalonic acidemia patients. Fur-
Biochemical parameters in MMA patients Figure 5
Biochemical parameters in MMA patients. Plasma MMA levels 
(µM) and 24-hour urine MMA output (mmol/kg/d) in non-
transplanted patients (muto-patients 1–4) with preserved 
renal function (A) compared to patients who have received 
solid organ transplants (L(A)KT, LKT) (B). * p-values for the 
average plasma MMA concentrations and MMA output from 
the untransplanted patients versus the transplanted patients. 
Neither the plasma metabolites [F(1,4) = 0.40, p = 0.56] or 
the MMA output [F (1,4) = 0.70, p = 0.44] was significantly 
different between the groups.BMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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thermore, because both liver-kidney transplant patients
had intact renal function and normal-functioning livers
that would metabolize gut-derived propionate, the MMA
in these patients must originate principally in other
organs.
Direct comparison to the pre-transplant state in solid
organ transplant patients was not possible because they
had not been studied when renal function was intact nor
in the same fashion described in this report. For this rea-
son, the transplant patients were compared to a group of
untransplanted patients with the same enzymatic pheno-
type and preserved renal function who were treated with
low protein, high-energy diets. Future efforts to character-
ize the metabolic parameters in MMA solid organ trans-
plant recipients might benefit from standardized pre- and
post- operative regimens to measure metabolic parame-
ters in all patients. Clearly, this will be an important clin-
ical and research problem to address, especially since the
number of MMA transplant recipients to date is small but
likely to increase as more patients are identified through
newborn screening.
In humans, approximately 40 percent of the body mass is
skeletal muscle, which plays a major role in branched-
chain amino acid catabolism and fatty acid oxidation [48-
51]. Because branched-chain amino acid catabolism and
odd-chained fatty acid oxidation produce the bulk of the
MMA observed in non-transplanted patients[52], the sim-
plest hypothesis to unify the observations from the
murine and human studies is that MMA is being gener-
ated by the skeletal muscles in both species. Indeed, when
methylmalonyl-CoA mutase was previously measured in
different murine tissues, skeletal muscle possessed signif-
icant holo- and apo- enzyme activity. Furthermore, the
promoter was more complex than seen in generic "house-
keeping" genes and the Mut gene and protein appeared to
be subject to significant regulation at the transcriptional
and post-translational levels [53]. To directly examine the
skeletal muscle and other tissues for the relative abun-
dance of enzyme, we used Western blot analysis to exam-
ine tissue extracts from a wild type mouse and found that
the skeletal muscles contained a large amount of immu-
noreactive enzyme, grossly comparable to the relative
amounts present in the kidney and liver (see additional
file 6 for a Western analysis of murine tissues). Thus sev-
eral lines of evidence indicate that the enzyme is
expressed, active and abundant in the skeletal muscle.
Skeletal muscle is also an important site of branched-
chain amino acid (BCAA) oxidation [50,51], a process
suspected to contribute approximately 50 percent of the
MMA load observed in humans [52]. The branched-chain
alpha-ketoacid dehydrogenase complex is an enzyme
involved in branch-chain aminoacid oxidation, which is
inhibited via phosphorylation by the branched-chain
alpha-ketoacid dehydrogenase kinase [54]. Methylmalo-
nyl-CoA has previously been shown to inhibit branched-
chain alpha-ketoacid dehydrogenase kinase activity [55].
In the setting of methylmalonic acidemia, methylmalo-
nyl-CoA accretion may increase the activity of the
branched-chain alpha-ketoacid dehydrogenase complex
by inhibiting the branched-chain alpha-ketoacid dehy-
drogenase kinase in the skeletal muscle beds, setting up a
physiological forward feeding circuit for MMA produc-
tion. Increased MMA production through such a mecha-
nism might also contribute to the significant
methylmalonic acidemia seen in the transplant patients.
The possibility that the MMA concentrations in the tissues
of the knock-out mice may be influenced by the develop-
mental regulation for BCAA catabolism will require fur-
ther examination, especially since the regulation of BCAA
catabolism in mice has not been extensively studied.
Additionally, the precursors of MMA may vary over time,
with odd-chained fatty acids potentially providing a
major contribution to the metabolite load in the mice and
humans, especially given the evidence from patient stud-
ies demonstrating that odd chained fatty acids are
increased in patients with propionate metabolic disor-
ders[56,57].
The clinical studies presented here include determination
of whole body MMA output in muto patients, a measure-
ment that has previously been demonstrated to be an
effective means to carefully describe whole body MMA
metabolism[44]. Previous clinical reports [33,34] and the
studies presented here firmly demonstrate that enzymatic
correction of the liver and kidney in affected patients by
transplantation does not always greatly lower the circulat-
ing MMA load. However, liver transplantation patients do
realize complete protection from systemic metabolic
decompensation. This suggests a tissue-specific response
or maladaption to the inherent biochemical lesion in the
native liver, and possibly other organs. Our results indi-
cate that modulating metabolism in the skeletal muscle –
by gene replacement or pharmacological means – may
represent an effective strategy to lower MMA levels and
increase metabolic capacity in affected patients. Other dis-
orders of intermediary metabolism that feature impaired
branched chain aminoacid oxidation, such as propionic
acidemia, might also benefit from these approaches.
Conclusion
In summary, this report describes the construction and
characterization of a new murine model of methyl-
malonic acidemia and its use to examine organ specific
contributions to MMA production in the human condi-
tion in the post-transplant state. The targeted allele is null,
designed for genomic engineering, and correctable by len-
tiviral transduction. The combined observations from theBMC Medical Genetics 2007, 8:64 http://www.biomedcentral.com/1471-2350/8/64
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murine metabolite studies and patient investigations indi-
cate that during homeostasis, a large portion of circulating
MMA has an extra-heptorenal origin and likely derives
from the skeletal muscle. Our studies suggest that modu-
lating skeletal muscle metabolism may represent a strat-
egy to increase metabolic capacity in methylmalonic
acidemia as well as other organic acidurias. This mouse
model will be useful for further investigations exploring
disease mechanisms and therapeutic interventions in
methylmalonic acidemia, a devastating disorder of inter-
mediary metabolism.
List of Abbreviations
MMA (methylmalonic acidemia), MUT (human methyl-
malonyl-CoA mutase), Mut (murine methylmalonyl-CoA
mutase),  muto  (vitamin B12 non-responsive methyl-
malonic acidemia), MEF (murine embryonic fibroblasts),
CMV (cytomegalovirus), LKT (liver-kidney transplanta-
tion), eGFP (enhanced green fluorescent protein), 2-MC
(2-methylcitrate), BCAA (branched chain amino acids)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
RJC produced reagents, executed experiments, interpreted
data and drafted the manuscript; JS coordinated patient
care, performed clinical studies and analysis and helped
draft the manuscript; HF produced recombinant ES cells;
MT performed experiments; SS performed metabolite
analysis and interpretation; RA performed metabolite
analysis and interpretation; KHK produced recombinant
ES cells and helped draft the manuscript; HHK aided with
data analysis and helped draft the manuscript; CPV con-
ceived the knock-out model, produced reagents, executed
experiments, performed clinical studies, interpreted data
and drafted the manuscript. All authors read an approved
the final version of the manuscript.
Additional material
Acknowledgements
Patient participation and physician referral were critical to these studies. 
Advice and encouragement from Drs Gerard T. Berry (Harvard University) 
and Edward M. Kaye (Genzyme Incorporated) were instrumental in the 
beginning of this project. Statistical advice was provided by Laura N. Ven-
ditti of Biomedical Statistical Consulting (Wynnewood, PA USA). This work 
was supported in part by NIH grant DK049210 to KHK. MT received fund-
ing from the Organic Acid Association-MMA Research Fund; RC, JS and 
CPV were supported, in part, by the Intramural Research Program of the 
National Human Genome Research Institute, National Institutes of Health.
Additional file 1
Genotype and screening assays. (A). A 2% agarose gel showing the results 
of the genotyping reaction across the 5' loxP site. Lanes 1–4, 6, and posi-
tive control are from heterozygote animals and exhibit two bands: 190 bp 
(wild-type) and 225 bp, which contains the flank sequences as well as the 
loxP site. Lane 5, homozygous for the wild-type Mut locus, has a single 
wild-type band while lane 7, a homozygous Mut knock-out, has a single 
loxP site. Para-nitroanaline (PNA) reactivity of 3.5 µl of urine from each 
animal yields an emerald green positive reaction for the Mut mutant. The 
bottom of the panel shows the standards for the PNA reaction: A-10 mM, 
B-100 mM, C-1 mM, D-blank. The affected animal (number 7) appears 
to have a urinary MMA concentration between 10 and 100 mM.




Primers for PCR and RT-PCR




Western analysis of wild-type and Mut embryonic fibroblast extracts. 
Western blotting using anti-mutase antisera reveals a band of ~80 kd in 
the wild-type extracts that is completely absent from the Mut null MEF 
line. Recombinant murine methylmalonyl-CoA mutase expressed in yeast 
served as a positive control (Y) and is located next to the marker (M) lane. 
The sizes of the molecular weight standards in kilodaltons are indicated. 
Anti-actin antibodies were used to control for the amount of protein loaded 
per well.




Methylmalonic acid fold change by tissue type. The values are averages 
from prenatal [embryonic day 19] (n = 3), neonatal [8–12 hour] (n = 
3) and metabolic crisis [20–24 hour] (n = 2) affected animals. The fold 
change is plotted for each time point compared to control littermates (n = 
2).




2-Methylcitrate I/II Ratios in Mouse Organs




Tissue distribution of murine methylmalonyl-CoA mutase. Western anal-
ysis of tissue extracts prepared from a wild-type mouse. 10 µg of total pro-
tein were loaded in each lane and probed with anti-mutase antibodies or 
anti-actin antibodies. A recombinant mouse methylmalonylCoA mutase 
protein (labeled yeast) served as the positive control. The marker lane (M) 
and the sizes of the molecular weight standards in kilodaltons are indi-
cated.
Click here for file
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